Structure and Dynamics of RNA and Protein-RNA Complexes

描述(申请人提供)：这项建议的主要目标是开发改进的方法，通过核磁共振(核磁共振)光谱来探测RNA的结构和动力学，并应用核磁共振和生化方法来了解RNA适配子用来识别具有高亲和力和特异性的蛋白质靶标的分子决定因素。最先进的核磁共振技术将被用于研究体外选择的RNA适配子，它是一种有效和特异的血管生成抑制物。目标1将开发用于确定RNA的核磁共振溶液结构的改进方法。其中一个重点将是开发用于测量剩余偶极耦合(RDC)数据的新的对准技术。这些RDC提供了远程结构信息，这对于RNAs等扩展分子的结构确定至关重要。将开发用于RNA的顺磁标签，并将其用于改善RNA的全局和局部结构。此外，最近开发的快速获取高分辨率四维核磁共振的方法将被应用于RNA的共振指定。这些方法允许在当前方法的一小部分时间内获得高分辨率的高维谱，从而极大地促进了RNA的核磁共振结构的确定。目的2研究RNA适体药物Macugen抑制其生理靶点血管内皮生长因子(VEGF)的分子机制。Macugen最近被FDA批准用于治疗湿性老年性黄斑变性，这是老年人失明的主要原因。Macugen与血管内皮生长因子高亲和力和特异性结合，从而阻断血管内皮生长因子与细胞表面受体的结合。多维异核核磁共振将用于确定Macugen与血管内皮生长因子的肝素结合结构域(HBD)结合的溶液结构。这些结构研究将与HBD突变体的生化研究相辅相成，以更好地了解导致VEGF-Macugen复合体高亲和力的特定相互作用。目标3将研究一系列与HBD高亲和力结合的RNA适配子。目标是识别识别HBD不同表面的适体。这项研究将确定适配子用来识别他们的目标蛋白的不同机制，并将导致更好地理解细胞RNA用来识别他们的蛋白质伙伴的分子决定因素。PUBLIC健康相关性：这项建议将研究最近FDA批准的RNA适配子药物Macugen与其细胞靶点血管内皮生长因子的相互作用。Macugen用于治疗湿性老年性黄斑变性，这是50岁以上人群失明的主要原因。

DESCRIPTION (provided by applicant): The primary goals of this proposal are to develop improved methods for probing the structure and dynamics of RNAs by nuclear magnetic resonance (NMR) spectroscopy and the application of NMR and biochemical methods to understand the molecular determinants that RNA aptamers use to recognize their protein targets with high affinity and specificity. State-of-the-art NMR techniques will be used to study an in vitro selected RNA aptamer that is a potent and specific inhibitor of angiogenesis. Aim 1 will develop improved methods for NMR solution structure determinations of RNA. One focus will be development of novel alignment techniques for measurement of residual dipolar couplings (RDCs) data. These RDCs provide long-range structural information which is critical for structure determinations of extended molecules such as RNAs. Paramagnetic tags for RNA will be developed and used to improve the global and local structures of RNAs. Additionally, recently developed methods for rapid acquisition of high-resolution four-dimensional NMR will be applied to resonance assignments of RNA. These methods have the potential to greatly facilitate NMR structure determinations of RNA by allowing acquisition of high-resolution high-dimensional spectra in a fraction of the time of current methods. Aim 2 will study the molecular mechanism of inhibition of the RNA aptamer drug, Macugen, for its physiological target, vascular endothelial growth factor (VEGF). Macugen was recently approved by the FDA for treatment of the wet-form of Age Related Macular Degeneration, which is the leading cause of blindness in the elderly. Macugen binds with high affinity and specificity to VEGF; thereby blocking binding of VEGF to cell surface receptors. Multi-dimensional heteronuclear NMR will be used to determine the solution structure of Macugen bound to the heparin-binding domain (HBD) of VEGF. These structural studies will be complemented with biochemical studies of HBD mutants to better understand the specific interactions that lead to high affinity of the VEGF-Macugen complex. Aim 3 will study a series of RNA aptamers that all bind with high affinity to the HBD. The goal is to identify aptamers that recognize different surfaces of the HBD. This study will identify different mechanisms that aptamers employ to recognize their target protein and will lead to a better understanding of the molecular determinants that cellular RNAs use to recognize their protein partners.PUBLIC HEALTH RELEVANCE: This proposal will study the recently FDA-approved RNA aptamer drug, Macugen, interacting with its cellular target, vascular endothelial growth factor. Macugen is used to treat the wet-form of Age- Related Macular Degeneration, the leading cause of blindness in people over age 50.